Promethera has developed its technologies by using allogeneic mesenchymal and hepato-biliary stem cells as well as hepatocytes. These are isolated, purified and expanded from human livers unsuitable for transplantation – however, meeting all eligibility criteria – and delivered directly at the patient’s bedside.
Promethera’s pioneering approach enables the use of each such donated livers. Indeed, one processed liver can allow for the treatment of several patients instead of the conventional transplant model of one liver per patient.
The company has established and is continuously optimizing its manufacturing set-up to meet today’s and future requirements and demand for its cell therapy product.